GlassScriptPhysician profile
Danielle Moriarity
NPI 1760022107
$4,259.54
in general payments reported to CMS, 2019-2025
22 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.34 · 2022: $616 · 2023: $1,193 · 2024: $1,335 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,562.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,665.01 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $504.00 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $481.98 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $340.87 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $272.59 | 2023-2025 | |
| Amgen INC. | $200.06 | 2023-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $168.08 | 2023 | Xarelto, Spravato |
| Dexcom, INC. | $80.85 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $74.91 | 2023-2025 | |
| Indivior INC. | $62.86 | 2024-2025 | Sublocade |
| Exact Sciences Corporation | $62.59 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $47.84 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.81 | 2023-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $44.84 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $40.86 | 2024-2025 | Gardasil 9, Gardasil, Capvaxive |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $40.78 | 2023 | Quviviq |
| Abbott Laboratories | $24.53 | 2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $22.72 | 2025 | General - Pain Management |
| Amneal Pharmaceuticals LLC | $22.26 | 2023 | Unithroid |
| Alkermes, INC. | $19.95 | 2025 | Vivitrol |
| Janssen Biotech, INC. | $18.16 | 2025 | Tremfya |
| Otsuka America Pharmaceutical, INC. | $17.99 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Moriarity listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.